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Abstract
Among metabolic diseases, diabetes is considered
one of the most prevalent throughout the world.
Currently, statistics show that over 10% of the
world's aged population (60 years and older) suffers
from diabetes. As a consequence, it consumes a
considerable proportion of world health expendi-
ture. This review considers both past and current
research into the molecular basis of insulin resis-
tance found in type II diabetes and focuses on the
role of inositol-containing phospholipid metabo-
lism. It has been firmly established that the activa-
tion of phosphatidylinositol 3-kinase (PI3-K) is im-
portant for the propagation of the metabolic actions
of insulin. In addition to the 3-phosphorylated
phosphatidylinositols formed via the action of
PI3-K, the glycosyl-phosphatidylinositol/inositol
phosphoglycan (GPI/IPG) signaling component is
also strongly implicated in mediating numerous
metabolic actions of insulin. Although all the ele-
ments within the type II diabetes phenotype have
not been fully defined, it has been proposed that
defects in insulin transmembrane signaling through
malfunction of inositol-containing phospholipid
metabolism and absenteeism of the generation of
phospholipid-derived second messengers may be as-
sociated with the appearance of the type II diabetic
phenotype. Pharmaceutical approaches using syn-
thetically produced IPG analogues, which them-
selves mimic insulin's actions, alone or in combina-
tion with other drugs, may lead the way toward
introducing alternative therapies for type II diabetes
in the coming years.
Introduction
Diabetes mellitus is the term used to define the
absolute or partial impairment of insulin action
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on the cells of target tissues that leads to abnor-
mally elevated blood glucose concentrations. A
positive diagnosis of diabetes is made when a
fasting plasma glucose level is >7.8 mM or a
plasma glucose level is >1 1.1 mM during an oral
glucose tolerance test (measured at two time
points, before 2 hr and at 2 hr) (1-3). The con-
sequence of such impairment of insulin function
is the tendency toward the onset of chronic com-
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plications such as premature cardiovascular dis-
ease, retinopathy, neuropathy, nephropathy,
and macrovascular disease (4,5). When no treat-
ment against diabetes is administered, severe or-
gan damage gradually leads to the death of af-
flicted subjects.
There are two types of diabetes. Type I dia-
betes (also termed insulin-dependent diabetes
mellitus) is the result of autoimmune destruction
of the pancreatic beta cells, which gives rise to a
deficiency in insulin secretion (6-8). To circum-
vent this lack of insulin secretion, insulin is usu-
ally self-administered subcutaneously to main-
tain an approximately normal blood glucose
concentration. Type II diabetes (also known as
non-insulin-dependent diabetes mellitus) is
caused by both insulin deficiency and insulin
resistance. This insulin resistance, particularly
within skeletal muscle, liver, and adipose tissue,
leads to pronounced hyperglycemia as glucose
transport into cells is severely reduced (3,9). De-
spite the fact that the etiology of type II diabetes
is less well understood than that of type I, avail-
able evidence points to both genetic and nutri-
tional/behavioral factors (type of diet, obesity,
physical exercise) as possible regulators of the
onset of type II diabetes (10, 11).
Molecular Mechanisms of Insulin
Action: Via Proteins and
Phospholipids
Insulin delivers its signal through binding to its
high-affinity cell surface receptor. This protein is
a tetrameric complex consisting of two a and two
,B subunits. The intracellular domains of the 1B
subunits contain intrinsic protein tyrosine kinase
activity and are involved in the initiation of in-
sulin-dependent transmembrane signaling
events. The early signal transduction events in-
volve the autophosphorylation of its receptor on
tyrosine residues and of the insulin receptor sub-
strates 1, 2, and 3 (IRS-1, -2, and -3), leading to
the generation of docking sites on both the insu-
lin receptor and the IRS proteins for SH2 and
SH3 domain-containing proteins. These pro-
teins, which include both enzymes and adapters,
initiate a multitude of downstream signals that
regulate the phosphorylation state of a wide va-
riety of proteins and some phospholipids (12-
14).
Despite our vast knowledge of the role of
enhanced protein phosphorylation/dephosphor-
ylation in response to insulin, relatively little is
known about insulin's effects on phospholipid
metabolism and its possible role in explaining
insulin resistance in type II diabetes. The connec-
tion between insulin-mediated signal transduc-
tion and phospholipids received its breakthrough
in 1986 when Cuatrecasas' laboratory provided
evidence that the previously described "insulin-
stimulated water-soluble modulators of enzyme
activity" were in fact derived from glycolipids
(15). This led to the rapid appearance of numer-
ous reports within the literature confirming that
insulin, and other growth factors and classical
hormones, stimulated the hydrolysis of similar
glycolipids (glycosyl-phosphatidylinositol, now
termed GPI) generating water-soluble second
messengers termed inositol phosphoglycan (IPG)
(16,17). This process, drawn schematically in
Figure 1, indicates GPI phospholipid hydrolysis
leading to the generation of IPG. As interest in
the GPI/IPG signaling system during insulin sig-
nal transduction grew, investigators in diabetic
research attempted to understand the metaboli-
cally altered phenotype by considering phospho-
lipid-derived second messengers and their role in
the control of intermediary metabolism (18).
IPG: A Requirement for Functional
Metabolic Actions of Insulin?
Positive insights into a relationship between the
insulin GPI/IPG signaling system and type II di-
abetes soon became apparent after examining
differences between insulin-stimulated GPI hy-
drolysis in cells isolated from diabetic and normal
rats. Three independent investigations revealed
that, in addition to less GPI being present, insu-
lin-stimulated GPI hydrolysis in cells exhibiting
insulin resistance was absent or severely im-
paired (19-21). IPG, the product of GPI hydro-
lysis, is considered a potential insulin second
messenger on the basis of three lines of evidence:
(1) by itself it can mimic a large number of the
metabolic actions of insulin (both in vivo and in
vitro, see later and Table 1), (2) anti-IPG anti-
bodies can attenuate several in vivo actions of
insulin, and (3) synthetically produced chemical
IPG analogues exhibit in vitro and in vivo insu-
lin-like activities (see later and ref. 17). The first
of these three lines of evidence has been widely
used to investigate differences in gluconeogene-
sis and lipogenesis between normal and diabetic
experimental models. In doing so, the results
have underlined the importance of this novel
insulin-stimulated signaling pathway. At least
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Fig. 1. Structure and hydrolysis of a GPI phos-
pholipid by phospholipases D (PLD) and C
(PLC) generating IPG type A and PA, and IPG-
1,2-(cyclic phosphate) type A and DAG. Origi-
nally it was proposed that the responsible enzyme
was a PLC, however, recent studies suggest that PLD
is also capable of generating biologically active IPG
type A from GPI (24,25). Ins, myo-inositol; GlcN,
glucosamine; PA, phosphatidic acid; DAG, diacyl
glycol.
two types of IPG exist. The structures of the IPGs
have been refined but not totally elucidated. IPG
type A contains myo-inositol and glucosamine
(22), whereas IPG type P contains a-pinitol (3-
0-methyl D-chiro-inositol) and galactosamine as
core components (23). Both types of IPG have
been shown to additionally contain neutral sugars
and phosphate residues. The origin of IPG type A is
thought to be myo-inositol-containing GPI, as both
phospholipase C (PLC)- and phospholipase D
(PLD)-mediated hydrolysis of GPI yield biologically
active IPG molecules (17,22,24,25). The same can-
not be said, however, for IPG type P, as important
differences are evident. Stereochemically, the
favored configuration of chiro-inositol within phos-
phoinositides for phospholipase C-mediated hy-
drolysis is that of the L-diastereomer (26). How-
ever, Lamer's group has claimed that IPG type P
contains D-chiro-inositol (23,27), thereby putting in
doubt its phospholipid origin as D-chiro-inositol-
containing phosphoinositide-specific PLCs have
thus far remained elusive. Within a few years of
the publication of a preliminary structure of GPI,
a synthetic chemical analogue of IPG type A (1-D-
6-0- (2-amino-2-deoxy-a-D-glucopyranosyl) -myo-
inositol 1,2-(cyclic phosphate)) was reported. This
compound exhibited both insulin-mimetic proper-
ties (stimulation of lipogenesis in rat adipocytes,
ref. 28) and insulin-like growth factor I (IGF-I)-
mimetic properties (stimulated mitogenesis and
Jun and Fos oncogene expression in the developing
chicken inner ear, refs. 29-31; I. Varela-Nieto,
D. R. Jones, Y. Leon, H. N. Caro, T. W. Radema-
cher, unpublished observations). It appears that
the myo-inositol 1,2-(cyclic phosphate) portion of
the above IPG type-A analogue is important, as
(1 -D-6-0-(2-amino-2-deoxy-a-D-glucopyranosyl) -
myo-inositol 1-phosphate is an inactive IPG type-A
analogue (32). The opening of a myo-inositol 1,2-
(cyclic phosphate) moiety to form a myo-inositol
1-phosphate within IPG type A could be a method
for the cessation of its biological activity in vivo.
This decyclization could be achieved by the action
of the enzyme cyclic inositol phosphohydrolase
(33). In addition to I-D-6-0-(2-amino-2-deoxy-a-
D-glucopyranosyl) -myo-inositol 1,2- (cyclic phos-
phate), the synthesis of 6-0-(2-amino-2-deoxy-a-
D-glucopyranosyl)-D-chiro-inositol- 1-phosphate, an
analogue of IPG type P, has been reported. This
latter compound also shows both insulin-mi-
metic (34) and distinct IGF-I-mimetic (e.g., dif-
ferentiation of the cochleovestibular ganglion in
the developing chicken inner ear, ref. 35) at-
tributes. A variation on the structure of the
above-mentioned IPG type-P analogue has re-
cently been reported. The pseudodisaccharide
consisting of a-pinitol linked to galactosamine,
termed INS-2, is able to stimulate testosterone
production in human thecal cells to an extent
similar to that of insulin (36,37). Furthermore,
synthetic inositol-glycan moieties mimic insulin
action, as discussed in detail below. An inspec-
tion of the biological properties of IPG type-A
and type-P analogues reveals that they show
contrasting biological effects that correspond to
those of purified IPG subtypes (17,38,39). These
observations reinforce the claim that IPG is a true
second messenger and is essential in many met-
abolic, mitogenic, and differentiation processes.
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Table 1. Insulin mimetic effects of IPG type A (A), IPG type P (P), and their analogues from different
sources
Whole Cells Cell Extracts
Enzymatic Activity or
Biological Activity Effect Phosphorylation Effect
Lipolysis (A, A*, A')
Lipogenesis (A, A*, A')
GPAT (A*, A')
Phospholipid methyltransferase (A)
Steroidogenesis (A, P*)
Glucose transport (A, A*, A")
GLUT4 translocation (A*, A')
Acetyl-CoA carboxylase (A)
Glycogen phosphorylase a (A)
Pyruvate kinase (A)
Glucose oxidation (A)
Glucose production (A)
Lactate accumulation (A)
Glycogen synthesis (A, P, A*, A')
Glycogen synthase kinase-3 (A*, A")
Tyrosine aminotransferase (A)
Protein phosphorylation (A, A*, A")
cAMP levels (A)
PI 3-kinase (A*, A-)
Myelin basic protein kinase (A)
Mitogen activated kinase (A')
Protein kinase B phosphorylation (A')
Fructose-2,6-P2 levels (A)
Ion channels (A)
Ca2+_Mg2+ ATPase (A)
Ca2+ entry (A)
Amino acid transport (A)
Protein synthesis (A, A')
Specific mRNA levels (A)
DNA and RNA synthesis (A)
Cell proliferation (A, P)
Insulin secretion (A)
Cell differentiation (neurogenesis) (P)
Inhibition
Stimulation
Stimulation
Inhibition
Stimulation
Stimulation
Stimulation
Stimulation
Inhibition
Stimulation
Stimulation
Inhibition
Stimulation
Stimulation
Inhibition
No effect
IStimulation
Inhibition
Inhibition
Stimulation
Stimulation
Stimulation
Stimulation
Stimulation
Modulation
Stimulation
Inhibition
Stimulation
Stimulation
IStimulation
Inhibition
Stimulation
Stimulation
Inhibition
Stimulation
cAMP phosphodiesterase (A)
Pyruvate dehydrogenase (A)
PDH phosphatase (P)
Glucose-6-phosphatase (A)
Fructose-1,6-biphosphatase (A)
Adenylate cyclase (A)
cAMP-kinase (A)
Casein kinase II (A)
Glycerol-3P acyltransferase (P)
ATP citrate lyase (A)
Galactolipid sulfotransferase (A)
Protein phosphatase 2C (P)
Adapted and updated from Jones and Varela-Nieto (17). A*, A phosphoinositolglycan-peptide (PIG-P) (57,58,61); A', various
chemically synthesized PIG-P analogues (38,39); GPAT, glycerol-3-phosphate acyltransferase P*, an analog of IPG type P (INS-2)
consisting of a-pinitol and galactosamine (36) PDH, pyruvate dehydrogenase.
Despite the uncertainty of the precursor
and/or origin of IPG type P, the role of chiro-
inositol and IPG type P in type II diabetes has
been the subject of multiple and enlightening
investigations. Kennington and colleagues re-
ported that in patients suffering from type II
Stimulation
Stimulation
Stimulation
Inhibition
Inhibition
Inhibition
Inhibition
Biphasic
Stimulation
Stimulation
Inhibition
Stimulation
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diabetes and in diabetic Rhesus monkeys there
was a decreased urinary excretion of chiro-inosi-
tol compared to that seen in healthy controls.
Furthermore, chiro-inositol in IPG type-P prepa-
rations from type II diabetic human biopsy mus-
cle tissue was undetectable (40). A follow-up
report by Asplin and co-workers indicated that in
type II diabetics both the amount of IPG type P
and its bioactivity were reduced in hemodiasy-
late, urine, and muscle compared to normal sub-
jects (41). These and other reports (which have
included results of the analysis of inositol isomer
excretion and of IPG preparations from diabetics
of differing nationalities) tentatively suggest that
a decrease in chiro-inositol and IPG type-P bio-
synthesis may be underlying features of type II
diabetes and that the urinary chiro-inositol-to-
myo-inositol ratio could be considered a clinical
marker for predicting the onset of diabetes at an
early stage (42). Another direct report indicating
the abnormality of IPG type-P production in di-
abetics is that from Shaskin and colleagues (43),
whose results clearly indicate that in a group of
insulin-resistant subjects, glucose ingestion failed
to increase the serum concentration of IPG type
P compared to that seen in healthy controls. Pak
and colleagues have addressed the metabolism of
both myo- and chiro-inositol in the diabetic Goto-
Kakizaki rat compared to its normal healthy
counterpart (44). Their findings indicate that
there exist significant differences in the in vivo
interconversion of the inositol isomers in their
free unconjugated form and at the phosphoino-
sitide level between the two rat phenotypes. This
clearly underlines the importance of correct ino-
sitol isomer homeostasis, particularly in insulin-
sensitive tissues.
The two biochemical assays principally used
to define the biological activity of the IPG sub-
types are the IPG type A-mediated inhibition of
protein kinase A and the stimulation of pyruvate
dehydrogenase phosphatase by IPG type P. As
mentioned previously, IPG molecules possess in-
sulin-mimetic properties. These properties,
which have been extracted from more than a
decade of research literature, are listed in
Table 1. Clearly, in most of the insulin-mimetic
observations, IPG type A was used because it
could be prepared through the in vitro hydrolysis
of purified GPI from various sources (22,45).
Also, IPG type P was perhaps viewed at first with
caution, as less information was available con-
cerning its structure and its source was unde-
fined, thereby limiting its use in experimental
studies. As techniques have improved for the
purification of both types of IPG, during the last
5 years, exciting evidence has shed new light on
the role of IPG subtypes in the mechanism of
insulin action. The first in vivo effects of IPG in
animal models showed that both IPG subtypes
were able to stimulate glycogen production in
the diaphragm of normal rats and transiently
reduce the elevated blood glucose in streptozo-
tocin-diabetic rats (46). This later observation
was reinvestigated using prolonged intravenous
delivery of IPG type P, which was able to nor-
malize the plasma glucose level in diabetic rats to
an extent to that observed with insulin (23). Two
further papers from Larner's laboratory have in-
dicated that insulin-dependent regulation of glu-
cose metabolism through IPG production is in-
deed more complicated than first thought. This
claim is substantiated by the finding that in the
plasma of type II diabetics there exists an ele-
vated (compared to control subjects) concentra-
tion of an antagonist of insulin-stimulated glu-
cose oxidation (47). Structural information
concerning this antagonist revealed that it con-
tained myo-inositol 1,2-(cyclic phosphate), galac-
tosamine, and mannose residues, indicating at-
tributes very similar to those of the two IPG
subtypes identified thus far. The biological activ-
ity of this inhibitor was found to be due to the
inhibition of IPG type P-stimulated pyruvate de-
hydrogenase phosphatase activity by shifting the
magnesium ion requirement of the enzyme to
the right (48).
Evidence suggests that the in vivo regulation
of IPG production in diabetic subjects must be
somehow perturbed, compared to that in healthy
controls. Directly or indirectly, upstream of insu-
lin-stimulatable GPI-hydrolyzing enzymes lay
the insulin receptor and the IRS proteins. Point-
mutated and kinase-deficient insulin receptors
fail to couple to the generation of IPG type A
through GPI hydrolysis (49,50), which implies
that in some way, insulin-stimulated tyrosine
phosphorylation events control GPI hydrolysis. It
is not known however, if this is due to a lack of
tyrosine phosphorylation of a phospholipase or
to malfunction of an adapter protein linking the
receptor to such an enzyme involving a tyrosine
phosphorylation event. In the case of insulin,
this tyrosine-dependent GPI hydrolysis may be
related to IRS protein expression and function. A
decreased level of IRS protein expression and
serine/threonine residue hyperphosphorylation
of IRS proteins give rise to signals that attenuate
insulin signal transduction and, furthermore, are
characteristic of insulin-resistant cells (51, 52). In
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Fig. 2. Schematic indicating a possible route
through which insulin could stimulate IPG
type-A generation in normal insulin-responsive
cells. Points within the proposed route at which a
blockade would result in the formation of insulin-
resistant cells are indicated. (1) Insulin receptor pro-
tein tyrosine kinase (point-mutated, kinase domain-
deleted, serine/threonine hyperphosphorylation).
(2) IRS proteins (expression levels, phosphorylation
5 I
1t
I I
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Metabolic effects
state). (3) Phospholipases C (PLC) or D (PLD) (ex-
pression levels, coupling). (4) GPI in the plasma
membrane (quantity, localization). (5) IPG type-A
transporter/receptor IPG type-A signal "transducing
protein" (expression levels, functionality). The open
symbols represents IPG derived from GPI-PLD-medi-
ated GPI hydrolysis. The closed symbols represent
IPG derived from GPI-PLC-mediated GPI hydrolysis.
addition, and equally intriguing, in IRS-2-knock-
out mice the type II diabetic phenotype was ob-
served, suggesting that insulin signaling through
this molecule is important for avoiding extracel-
lular hyperglycemia (53).
One of the signal transduction pathways that
is rapidly initiated by insulin is the activation of
PI3-K through its interaction with the IRS pro-
teins (54,55). The intricacies of this signaling
pathway are further complicated by the very re-
cent finding that insulin-dependent activation of
P13-K may be compartmentalized within cells.
This subcellular activation of P13-K in distinct cell
compartments appears to be dependent on the
localized expression of IRS proteins, whose pat-
tern is determined by the metabolic status of the
cell; this, in turn, is inferred by the diet of the
animal (56). Interestingly, an IPG type A-like
glycopeptide termed PIG-P, isolated from Saccha-
romyces cerevisiae, was able to elevate both IRS- 1-
associated P13-K activity and the tyrosine phos-
phorylation state of IRS- 1 without increasing
insulin receptor phosphorylation, indicating a
clear bypass of the insulin receptor (57). This was
a significant advance, in that it described a de-
fined signal transduction pathway for PIG-P,
which led to a physiological response: the trans-
location of GLUT4 glucose transporters to the
plasma membrane for the uptake of glucose from
the extracellular space (58). These GLUT4 glu-
cose transporters may be localized in membrane
caveolae (59), from which GPI and IPG have
been isolated (60). The mechanism by which
PIG-P exerts its insulin mimetic properties has
been investigated. A membrane-spanning pro-
tein labile to high-concentration salt, tryptic ac-
tion, and N-ethylmaleimide may act as a "trans-
ducer protein" with the cooperation of accessory
proteins, including caveolin, to cause the activa-
tion of a cytoplasmic tyrosine kinase that in turn
could phosphorylate the IRS proteins, thereby
leading to the early activation of PI3-K. This
PI3-K activation may represent the point at
which insulin-stimulated signal transduction via
its receptor and PIG-P action through the "trans-
ducer protein" converge (61). A series of back-
to-back reports immediately followed which ex-
amined the structural requirements for PIG-P
biological activity through the use of an exten-
sive range of chemically synthesized analogues.
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Interestingly, 1 -D-6-0- (2-amino-2-deoxy-a-D-
glucopyranosyl) -myo-inositol 1,2- (cyclic phos-
phate) -containing analogues exhibited the great-
est insulin-mimetic properties in rat adipocytes
and diaphragms (stimulation of P13-K, stimula-
tion of PKB/Akt, stimulation of glucose trans-
port, inhibition of glycogen synthase kinase-3
activity, stimulation of glycogen synthase, stim-
ulation of the MAP kinase pathway, and stimu-
lation of protein synthesis), which underline the
importance of this structure (38,39). Earlier
studies with an IPG-like molecule (similar to that
isolated from Saccharomyces cerevisiae) derived
from the GPI anchor of the variant surface gly-
coprotein of Trypanosoma brucei demonstrated in-
sulin-mimetic characteristics (inhibition of lipol-
ysis in rat adipocytes and gluconeogenesis in
hepatocytes) (62). This compound, again resem-
bling that of IPG type A, was subsequently
shown to cause the activation of the protein
serine/threonine phosphatase type 1 in rat adi-
pocytes (63). New light has recently been shed
on the mechanism of insulin-mediated activa-
tion of protein serine/threonine phosphatases.
Results concerning insulin-mediated activation
of glycogen synthase and inhibition of glycogen
phosphorylase in young, lean, adult Rhesus
monkey liver have implicated the involvement
of activated protein serine/threonine phospha-
tases types 1 and 2C. These activations may be
mediated by IPG type P (64,65). At the molecular
level, activation of protein phosphatase type 1
may be more complex because of the dual con-
trol exerted by both IPG type A and type P. When
threonine phosphorylated, DARRP-32 and
INH- 1 were potent inhibitors of protein phos-
phatase type 1. Very recently, IPG type A was
found to inhibit the PKA-mediated phosphory-
lation of DARRP- 32 and INH- 1, whereas IPG
type P was observed to directly stimulate protein
phosphatase-2C, thereby causing the dephos-
phorylation of phosphorylated DARRP-32 and
INH- 1 (66). With all the information available in
the literature, we were able to tentatively align a
pathway of molecular events, starting at the in-
sulin receptor and culminating at the point of
IPG generation in normal insulin-responsive
cells. This chain of events is illustrated in
Figure 2. Within the proposed scheme, possible
points, including the insulin receptor protein ty-
rosine kinase, IRS proteins, phospholipase type C
(or D), membrane GPI, and the IPG transporter
or IPG "transducer protein" at which defects
could exist, are indicated. A malfunction of any
of these components could be associated with the
onset of type II diabetes.
Closing Remarks
Without doubt, insulin signaling is a complex
event that involves the divergence of multiple
pathways downstream from its activated recep-
tor. Some of these signaling cascades converge to
control enzymes directly involved in intermedi-
ary metabolism, whereas others lead to the con-
trol of protein translation (67). Although the
roles of IPG types A and P are not completely
understood, we believe that they play important
roles in insulin signaling. Perhaps the most direct
evidence comes from the findings that, if the
enzyme responsible for the synthesis of myo-ino-
sitol-containing GPI is knocked out, then insulin
fails to stimulate glycogen, suggesting that the
presence of the GPI/IPG signaling system is a
prerequisite for the process in cells that use IPG
type A for glycogen production (68). However,
because IPG type P has been shown to stimulate
glycogen production in vivo in other cell types
(23,46), it seems plausible to suggest that there
are important cell-to-cell type differences in both
the generation and utilization of IPG subtypes to
mediate, in some cases, the same metabolic ef-
fects (36,69; I. Varela-Nieto, D. R. Jones, Y. Leon,
H. N. Caro, T. W. Rademacher, unpublished ob-
servations). In terms of metabolic control, insulin
elicits many of its effects through the activation
of PI3-K (54,5 5). In light of recent work in which
insulin-mimetic PIG-P and synthetic inositol-gly-
can analogues have been shown to activate var-
ious enzymes through the obligatory participa-
tion of P13-K, it could be possible that the type II
diabetic phenotype may manifest itself when the
levels of P13-K or its functionality are below
those in normal models (70-72).
It is hoped that in the near future, further
insights into the GPI/IPG signaling pathway will
emerge to allow us to extend our knowledge of
how diabetes causes its unwelcomed aberations
of intermediary metabolism and, in particular,
how chemically defined agents, such as IPG an-
alogues, may provide a possible starting point for
the design of drugs to combat type II diabetes.
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